Jacobio's China rights deal; Reneuron off the London exchange
Stem cell biotech Reneuron Group leaves the London Stock Exchange’s AIM: The company plans to stop trading on the exchange amid financial struggles, as it continues to look for investors. Reneuron...
View ArticleMerck opens London lab as it makes push into immunology and the UK
Merck has opened the doors to a new lab in London, part of the US drugmaker’s plans to grow its footprint in the UK and leverage its scientific expertise as it works to refill its pipeline. Merck, also...
View ArticleFDA approves Emergent vaccine for mpox as company plans to donate 50,000 doses
Emergent BioSolutions scored an expanded FDA approval for its single-dose vaccine, ACAM2000, to now include the prevention of mpox disease in people at high risk for an infection of the virus. The...
View ArticleIpsen sells priority review voucher for highest price since 2016
Ipsen Pharmaceuticals sold its priority review voucher to an unidentified “large global pharmaceutical company” for $158 million, it said this week, the highest publicly announced price for one of the...
View ArticleBiosecure vote slated for September
The House is planning to vote on the closely-watched Biosecure Act at the start of next month, the latest progression in efforts to rein in the influence of key China-based drug manufacturers. The...
View ArticleNovo Nordisk reveals post-hoc cardiovascular data for semaglutide
Novo Nordisk bolstered its heart disease data for semaglutide on Friday with additional analyses from a handful of trials. In a pooled analysis of certain heart failure patients from four studies,...
View ArticleFDA authorizes Novavax's updated Covid booster
The FDA has authorized emergency use of Novavax’s updated Covid booster, just over a week after clearing updated versions of mRNA boosters from Pfizer and Moderna. Novavax’s shot is the only...
View ArticleFDA authorizes Novavax Covid booster; Recursion nears key data readouts;...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleBayer’s Kerendia cuts heart death, failure and hospitalization by 16% in...
Less than a month after announcing success in a late-phase trial, Bayer has unveiled detailed results from its drug Kerendia in a subset of people with heart failure, sparking plans for a regulatory...
View ArticleClik here to view.
Sanofi’s BTK inhibitor goes 1-for-3 in key MS trials, slows disability...
The potential of Sanofi’s closely-watched BTK inhibitor in multiple sclerosis is coming into clearer view, amid plans to narrow the focus of the French company’s business drug development and get out...
View ArticleArrowhead spotlights key pancreatitis figures from Phase 3 lipid disease...
Arrowhead Pharmaceuticals has unveiled highly anticipated pancreatitis results from a late-phase trial of plozasiran for a rare lipid disorder, several months after reporting topline data. Arrowhead...
View ArticleClik here to view.
Exclusive: Duke spinout launches in hopes of prevailing with brain cancer...
Adaptin Bio is launching with plans to bring a bispecific T cell engager for glioblastoma, a deadly form of brain cancer, into the clinic. The company received FDA clearance to start its clinical...
View ArticleUpdated: Vaxcyte surges on Phase 1/2 data for 31-valent pneumococcal vaccine
Vaxcyte shares $PCVX jumped more than 40% Tuesday morning on the heels of Phase 1/2 data for its 31-valent pneumococcal conjugate vaccine, VAX-31, being tested in adults over 50. The company tested...
View ArticleExclusive: PatientPartner raises $7M to help pharma companies match patients...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) PatientPartner, a startup that matches patients with mentors who’ve gone through similar medical...
View ArticleClik here to view.
AI-focused biotech Recursion underwhelms with first Phase 2 readout
Recursion reported mixed data Tuesday from its first Phase 2 study, in a disappointing start to an expected frenzy of clinical results. The Salt Lake City-based biotech has forecast a stretch of about...
View ArticleClik here to view.
ProKidney axes one Phase 3 study, aims for 'expedited approval pathway' using...
ProKidney believes it will only need one Phase 3 trial to win an FDA approval for its kidney disease cell therapy, and will discontinue another to save cash. On Tuesday, the biotech said it will wind...
View ArticleDenali details accelerated approval plans; Jazz's $850M private offering
Plus, more news about Circle Pharma, Emergent, Cytokinetics, Nxera Pharma, Neurocrine Biosciences, Simcere Zaiming, TargetRx and Calliditas: Denali Therapeutics to seek accelerated approval in 2025:...
View ArticlePraxis' epilepsy drug reduces seizures by 46% in pediatric patients in Phase...
Praxis Precision Medicines released another batch of topline data from its epilepsy program on Tuesday, this time from the Phase 2 EMBOLD study investigating relutrigine in SCN2A and SCN8A...
View ArticleNovo Nordisk continues to grapple with patchy GLP-1 drug supply in Europe
All doses of Novo Nordisk’s Ozempic are expected to face “intermittent shortages” in Europe during the fourth quarter of the year, especially lower doses, supplies of which have “deteriorated,”...
View ArticleClik here to view.
Three Dyne executives leave as company reports new Duchenne drug data
Dyne Therapeutics’ new data on its experimental Duchenne muscular dystrophy drug is being overshadowed by the departure of several top executives. The biotech announced Tuesday that its chief operating...
View Article